Editorial · 2016
Conference abstractPublished 10 Aug 2015
The cost of improving patient care: Pharmaceutical pricing in the EU and USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
We are unfortunately subject to an optimistic bias when we evaluate how, and to what extent, drugs and other medical therapies will become available and accessible to patients on the global level in which pharmaceutical enterprises operate. In developed countries, the pricing and affordability of medicines is a controversial issue that highlights health and economic inequalities, and great challenges for the future. According to the New York Times article Lawmakers Look for Ways to Provide Relief for Rising Cost of Generic Drugs (November 24th 2014), â??the cost of many generic medications has increased so much over the past year that prices for many common generic drugs in the USA have surpassed those of their brand-name equivalents in other developed countries”. The issue of unaffordable healthcare is rendered more challenging with technological advances and the demographic growth of the geriatric population, including those with cancer and cardiac disease. Legislation can be instrumental in the creation of equitable solutions. The unique experience of the Republic of Malta as a small-island EU member state to manage healthcare access and drug entry into its national health service; implement regulatory requirements aimed at ensuring quality, safety, and efficacy of medicines and vaccines for human use; and the European Transparency Directive (Council Directive 89/105) which defines procedural requirements for pricing and reimbursement of medicinal products will be discussed. These issues must be taken into account since few of the hundreds of drugs in clinical development ever reach the stage of final approval, having failed to produce the anticipated results expected by the investigators. These trials can take up to 20 years to complete, and several billion dollars to reach the stage of approval or denial by the regulatory agency involved. When failing to demonstrate viability, pre existing expenditures are allowed to be passed onto the price the pharmaceutical company charges patients. In the cancer industry for example, most new drugs require the patient or insurance company to pay 50-100,000 dollars for a course of treatment which may not offer more than several months of improvement in the clinical response. It is essential that the legislators in each of the countries where the drug is to be introduced be able to negotiate a fee arrangement where the patient will not be denied treatment and the drug company be compensated reasonably for development costs.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 2018
Generic Drugs, A Need to the Public: USA and India- Government Plans to Reduce the Price of ANDA and List of Generic Drugs Approved in Year 2018
Conference abstract · 10 Dec 2018
Personalized Medicine: Reducing the cost and improving the effectiveness of drug therapy and health care
Conference abstract · 28 Apr 2016
Improving care across the pharmacy spectrum: Impacting all levels of pharmaceutical excellence through self improvement
Commentary · 2016
Collaboration and Socialization of Health Care Professionals to Improve the Clinical and Pharmaceutical Patients Care
More from this journal
The newest in Journal of Pharmaceutical Care & Health Systems.
Review article · 9 Jun 2025
Blood Fluid: The Unseen Currents That Bind Life and Death Together
Research article · 8 Jun 2025
Formulation and Antibacterial Evaluation of Acmella olaracea (Akarkara) Gummies Used for Toothache
Research article · 9 Apr 2025
Deep Vein Thrombosis: A Closer Look at a Silent Threat
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Care & Health Systems
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Anthia Zammit”

